Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma

By afschroeder • July 26, 2025

Ribas A, Milhem MM, Hoimes CJ, Amin A, Lao CD, Conry RM, Hunt JP, Daniels GA, Almubarak M, Shaheen M, Medina T, Barve M, Bishnoi S, Abdi E, Chisamore MJ, Guiducci C, Gomez-Romo J, Candia A, Gamelin E, Coffman RL, Janssen RS, Long GV. Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma. Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0987. Epub ahead of print. PMID: 40711475.

Tags: Hematology/Oncology, Publications

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]

Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients

Eckardt MA, Siena NM, Copeland AR, McCaw TR, Shehata MS, Lofftus SY, Graham DS, Dao HB, Singh AS, Chmielowski B, Federman N, Kadera BE, Kalbasi[...]

ASO Visual Abstract: Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over

Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. ASO Visual Abstract: Impact of Screening Mammography[...]